199 related articles for article (PubMed ID: 29243125)
1. Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma.
Hotton J; Agopiantz M; Leroux A; Charra-Brunaud C; Marie B; Busby-Venner H; Morel O; Guéant JL; Vignaud JM; Battaglia-Hsu SF; Gauchotte G
Virchows Arch; 2018 Apr; 472(4):623-633. PubMed ID: 29243125
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network.
Pouget C; Hergalant S; Lardenois E; Lacomme S; Houlgatte R; Carpentier C; Dehais C; Rech F; Taillandier L; Sanson M; Appay R; Colin C; Figarella-Branger D; Battaglia-Hsu SF; Gauchotte G
Brain Pathol; 2020 May; 30(3):465-478. PubMed ID: 31561286
[TBL] [Abstract][Full Text] [Related]
3. High expression of skp2 correlates with poor prognosis in endometrial endometrioid adenocarcinoma.
Kamata Y; Watanabe J; Nishimura Y; Arai T; Kawaguchi M; Hattori M; Obokata A; Kuramoto H
J Cancer Res Clin Oncol; 2005 Sep; 131(9):591-6. PubMed ID: 16080017
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
[TBL] [Abstract][Full Text] [Related]
5. Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome.
Agopiantz M; Forgez P; Casse JM; Lacomme S; Charra-Brunaud C; Clerc-Urmès I; Morel O; Bonnet C; Guéant JL; Vignaud JM; Gompel A; Gauchotte G
Virchows Arch; 2017 Oct; 471(4):521-530. PubMed ID: 28836043
[TBL] [Abstract][Full Text] [Related]
6. Methyl(R217)HuR and MCM6 are inversely correlated and are prognostic markers in non small cell lung carcinoma.
Vigouroux C; Casse JM; Battaglia-Hsu SF; Brochin L; Luc A; Paris C; Lacomme S; Gueant JL; Vignaud JM; Gauchotte G
Lung Cancer; 2015 Aug; 89(2):189-96. PubMed ID: 26013954
[TBL] [Abstract][Full Text] [Related]
7. GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma.
Canpolat T; Ersöz C; Uğuz A; Vardar MA; Altintaş A
Turk Patoloji Derg; 2016; 32(3):141-7. PubMed ID: 27562387
[TBL] [Abstract][Full Text] [Related]
8. Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients.
Binder PS; Peipert JF; Kallogjeri D; Brooks RA; Massad LS; Mutch DG; Powell MA; Thaker PH; McCourt CK
Am J Obstet Gynecol; 2016 Dec; 215(6):766.e1-766.e9. PubMed ID: 27457116
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic Association and Prognostic Value of Microcystic, Elongated, and Fragmented (MELF) Pattern in Endometrial Endometrioid Carcinoma.
Kihara A; Yoshida H; Watanabe R; Takahashi K; Kato T; Ino Y; Kitagawa M; Hiraoka N
Am J Surg Pathol; 2017 Jul; 41(7):896-905. PubMed ID: 28418994
[TBL] [Abstract][Full Text] [Related]
10. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
11. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
[TBL] [Abstract][Full Text] [Related]
12. Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
Edqvist PH; Huvila J; Forsström B; Talve L; Carpén O; Salvesen HB; Krakstad C; Grénman S; Johannesson H; Ljungqvist O; Uhlén M; Pontén F; Auranen A
Gynecol Oncol; 2015 Jun; 137(3):529-37. PubMed ID: 25858696
[TBL] [Abstract][Full Text] [Related]
13. Expression of minichromosome maintenance MCM6 protein in meningiomas is strongly correlated with histologic grade and clinical outcome.
Gauchotte G; Vigouroux C; Rech F; Battaglia-Hsu SF; Soudant M; Pinelli C; Civit T; Taillandier L; Vignaud JM; Bressenot A
Am J Surg Pathol; 2012 Feb; 36(2):283-91. PubMed ID: 22020044
[TBL] [Abstract][Full Text] [Related]
14. Cleaved caspase-3 expression is a potential prognostic factor for endometrial cancer with positive peritoneal cytology.
Ogane N; Yasuda M; Kato H; Kato T; Yano M; Kameda Y; Kamoshida S
Cytopathology; 2018 Jun; 29(3):254-261. PubMed ID: 29626374
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of Musashi-1 in endometrioid adenocarcinoma.
Ma L; Xu YL; Ding WJ; Shao HF; Teng YC
Int J Clin Exp Pathol; 2015; 8(5):4564-72. PubMed ID: 26191146
[TBL] [Abstract][Full Text] [Related]
16. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
17. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer.
Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D
Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443
[TBL] [Abstract][Full Text] [Related]
18. The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas.
Brüning A; Jückstock J; Blankenstein T; Makovitzky J; Kunze S; Mylonas I
Histol Histopathol; 2010 Nov; 25(11):1447-56. PubMed ID: 20865667
[TBL] [Abstract][Full Text] [Related]
19. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
20. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression.
Liu Z; Li J; Chen J; Shan Q; Dai H; Xie H; Zhou L; Xu X; Zheng S
BMC Cancer; 2018 Feb; 18(1):200. PubMed ID: 29463213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
